Matthew Beatty
@mbeattyphd.bsky.social
Cancer Immunologist | #TILTherapy Researcher | Avid traveler
Director, TIL Development Lab at Moffitt Cancer Center. @TILDevLab.bsky.social Views are my own.
#Immunology #Immunotherapy #Celltherapy #Immunosky
Director, TIL Development Lab at Moffitt Cancer Center. @TILDevLab.bsky.social Views are my own.
#Immunology #Immunotherapy #Celltherapy #Immunosky
Reposted by Matthew Beatty
Training programs in #celltherapy & #genetherapy through the International Society for Cell & Gene Therapy www.isctglobal.org/resources/tr...
December 12, 2024 at 1:21 PM
Training programs in #celltherapy & #genetherapy through the International Society for Cell & Gene Therapy www.isctglobal.org/resources/tr...
The results from IOV-COM-202 cohort 1a vs previous Iovance TIL trials in checkpoint refractory melanoma patients plus the NCI Surgery Branch's dataset definitely bring into question where in the sequence of therapies TIL ACT should sit. #TILTherapy
3) Dr #Stephanie_Goff @ #NCI #SurgeryBranch Gives fantastic overview #TIL #adoptive #immunotherapy /Evolving landscape, challenges, what is the future 4 #melanoma @melanomaau.bsky.social
@melanomaresearch.bsky.social @impactmelanoma.bsky.social
@sitcancer.bsky.social
#Bridge2025
#FinishCancer
@melanomaresearch.bsky.social @impactmelanoma.bsky.social
@sitcancer.bsky.social
#Bridge2025
#FinishCancer
December 5, 2024 at 12:13 PM
The results from IOV-COM-202 cohort 1a vs previous Iovance TIL trials in checkpoint refractory melanoma patients plus the NCI Surgery Branch's dataset definitely bring into question where in the sequence of therapies TIL ACT should sit. #TILTherapy
Reposted by Matthew Beatty
1) Dr #Stephanie_Goff @ #NCI #SurgeryBranch Gives fantastic overview #TIL #adoptive #immunotherapy /Evolving landscape, challenges, what is the future 4 #melanoma @melanomaau.bsky.social
@melanomaresearch.bsky.social @impactmelanoma.bsky.social
@sitcancer.bsky.social
#Bridge2025
#FinishCancer
@melanomaresearch.bsky.social @impactmelanoma.bsky.social
@sitcancer.bsky.social
#Bridge2025
#FinishCancer
December 4, 2024 at 10:10 AM
1) Dr #Stephanie_Goff @ #NCI #SurgeryBranch Gives fantastic overview #TIL #adoptive #immunotherapy /Evolving landscape, challenges, what is the future 4 #melanoma @melanomaau.bsky.social
@melanomaresearch.bsky.social @impactmelanoma.bsky.social
@sitcancer.bsky.social
#Bridge2025
#FinishCancer
@melanomaresearch.bsky.social @impactmelanoma.bsky.social
@sitcancer.bsky.social
#Bridge2025
#FinishCancer
Glad to see Bluesky get added to Altmetric’s tracking. It will be interesting to see how Bluesky holds up long term for disseminating research.
There are already many articles for which there is more attention on Bluesky than on other comparable micro-blogging sites, meaning the academic community and the general public have clearly adopted Bluesky as one of its core places to disseminate and discuss new research.
A Place of Joy.
A Place of Joy.
December 4, 2024 at 2:51 AM
Glad to see Bluesky get added to Altmetric’s tracking. It will be interesting to see how Bluesky holds up long term for disseminating research.
Very thankful to have a great group of members in the lab that can keep projects running smoothly while I step away from the lab for a week to spend time with family adopting a new city as our own. This year was #Edinburgh plus a day trip to Rosslyn Chapel, Hadrian's Wall, and Vindolanda.
December 2, 2024 at 6:36 PM
Very thankful to have a great group of members in the lab that can keep projects running smoothly while I step away from the lab for a week to spend time with family adopting a new city as our own. This year was #Edinburgh plus a day trip to Rosslyn Chapel, Hadrian's Wall, and Vindolanda.
Reposted by Matthew Beatty
1/23 Big news for the #ObenaufLab! So excited to finally share our new study providing another puzzle piece, why immunotherapy fails in many tumors, now out in @Nature 🧵👇 www.nature.com/articles/s41...
November 27, 2024 at 5:58 PM
1/23 Big news for the #ObenaufLab! So excited to finally share our new study providing another puzzle piece, why immunotherapy fails in many tumors, now out in @Nature 🧵👇 www.nature.com/articles/s41...
Reposted by Matthew Beatty
We're looking to recruit a postdoc with expertise in RNA biology to join our glyco-RNA team. Please share.
moffitt-cancer-center-careers.hctsportals.com/jobs/1808511...
moffitt-cancer-center-careers.hctsportals.com/jobs/1808511...
Postdoctoral Fellow – RNA Modifications in Melanoma in Tampa, FL - Moffitt Cancer Center CareersPostdoctoral Fellow – RNA Modifications in Melanoma in Tampa, FL - Moffitt Cancer Center Careers
Working at Moffitt Cancer Center is both a career and a mission. All employees are dedicated to patient care, research and education to advance our fight against this disease.
moffitt-cancer-center-careers.hctsportals.com
November 24, 2024 at 3:54 AM
We're looking to recruit a postdoc with expertise in RNA biology to join our glyco-RNA team. Please share.
moffitt-cancer-center-careers.hctsportals.com/jobs/1808511...
moffitt-cancer-center-careers.hctsportals.com/jobs/1808511...
Reposted by Matthew Beatty
Link to paper - Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients @mskcancercenter.bsky.social #CARTcells aacrjournals.org/clincancerre...
Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients
AbstractPurpose:. Chimeric antigen receptor (CAR) T-cell therapy is a potent immunotherapy for hematologic malignancies, but patients can develop long-term adverse events, including second primary mal...
aacrjournals.org
November 23, 2024 at 9:04 PM
Link to paper - Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients @mskcancercenter.bsky.social #CARTcells aacrjournals.org/clincancerre...
Very nice resource for anyone needing a starting point for figure illustration.
🎨 In case anyone need…
The NIH BioArt Source is an awesome library of *free* professionally drawn illustrations for scientific presentations or figures. Downloadable in HD. Thank you NIH for this invaluable tool 🙏!
Check it out 👇
bioart.niaid.nih.gov
The NIH BioArt Source is an awesome library of *free* professionally drawn illustrations for scientific presentations or figures. Downloadable in HD. Thank you NIH for this invaluable tool 🙏!
Check it out 👇
bioart.niaid.nih.gov
November 23, 2024 at 10:40 PM
Very nice resource for anyone needing a starting point for figure illustration.
Beautiful day and a packed crowd this morning for the 5k start at #MilesforMoffitt @TILDevLab.bsky.social
November 23, 2024 at 2:32 PM
Beautiful day and a packed crowd this morning for the 5k start at #MilesforMoffitt @TILDevLab.bsky.social
November 23, 2024 at 12:40 PM
Adding to the multitude of skyline pics in my feed with my recent trip to Tokyo. Here is one looking towards Mt Fuji from the Metropolitan Government Building along with the world’s largest projection mapping on the same building.
November 23, 2024 at 1:36 AM
Adding to the multitude of skyline pics in my feed with my recent trip to Tokyo. Here is one looking towards Mt Fuji from the Metropolitan Government Building along with the world’s largest projection mapping on the same building.
Reposted by Matthew Beatty
Pooled CRISPR screens with joint single-nucleus chromatin accessibility and transcriptome profiling go.nature.com/4hXER5O
Pooled CRISPR screens with joint single-nucleus chromatin accessibility and transcriptome profiling - Nature Biotechnology
MultiPerturb-seq profiles gene expression and chromatin accessibility in single-cell pooled CRISPR screen.
go.nature.com
November 21, 2024 at 2:26 PM
Pooled CRISPR screens with joint single-nucleus chromatin accessibility and transcriptome profiling go.nature.com/4hXER5O
It's that time again when we all crowd along the bay and take a morning run/walk for #CancerResearch. Looking forward to another year of #MilesforMoffitt with our #TILTherapy team, the #TurTILs. MilesforMoffitt.com
November 21, 2024 at 2:30 PM
It's that time again when we all crowd along the bay and take a morning run/walk for #CancerResearch. Looking forward to another year of #MilesforMoffitt with our #TILTherapy team, the #TurTILs. MilesforMoffitt.com
Seem to have received the collective migration memo over the weekend along with the rest of Med/Science Twitter. A little intro: #Immunology #Immunotherapy #ImmunoOncology #TCell #CellTherapy #TIL #Biotech #TranslationalResearch #CureCancer
November 19, 2024 at 2:03 AM
Seem to have received the collective migration memo over the weekend along with the rest of Med/Science Twitter. A little intro: #Immunology #Immunotherapy #ImmunoOncology #TCell #CellTherapy #TIL #Biotech #TranslationalResearch #CureCancer